News and Events

News

All categories

Earnings

Press Release

All years

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

April 23, 2025

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

April 21, 2025

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

March 25, 2025

Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

March 3, 2025

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

December 17, 2024

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

December 9, 2024

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

December 9, 2024

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

December 8, 2024

Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)

December 5, 2024

Affimed Reports Third Quarter 2024 Financial Results & Business Update

November 14, 2024

Events

All

Scientific

Investors

There are no events planned at the moment.

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)

Affimed Reports Third Quarter 2024 Financial Results & Business Update

Events